Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via a buyout of Siteone Therapeutics Inc., a privately held firm developing small-molecule sodium channel inhibitors, including a phase II-ready NaV1.8 inhibitor.
Siteone Therapeutics Inc. has provided details on the discovery of highly selective, potent, state-independent inhibitors of Nav1.7, a nonopioid target for the potential treatment of pain. While prior Nav1.7 inhibitors appear to bind the inactivated state preferentially, it was hypothesized that superior efficacy would be achievable by engaging all states/conformations of the channel.
Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
